anti-CD3/anti-GPC3 bispecific T-cell engager XmAb (Xencor)

N/A

Report date: 2026/03/19 16:58:25

Base Information

Drug Nameanti-CD3/anti-GPC3 bispecific T-cell engager XmAb (Xencor)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > T cell engagers

Mechanisms of ActionGlypican-3 modulatorsT cell surface glycoprotein CD3 modulators

TargetsGlypican-3T cell surface glycoprotein CD3

Therapy Area/IndicationsLiver Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesXencor Inc

China Registration ClassN/A

Develop Information

Active CompaniesXencor Inc

Inactive CompaniesN/A

Active IndicationsLiver Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A